910O Primary results of the phase III JAVELIN head & neck 100 trial: Avelumab plus chemoradiotherapy (CRT) followed by avelumab maintenance vs CRT in patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN)
Ezra E.W. Cohen(Moores Cancer Center), N. Lee(Memorial Sloan Kettering Cancer Center), Margarida Teixeira(Instituto Português de Oncologia de Coimbra Francisco Gentil), Makoto Tahara(National Cancer Center Hospital East), József Lövey(Országos Reumatológiai és Fizioterápiás Intézet), J. Chamois(Centre Hospitalier privé Saint Grégoire), Dmitri Pavlov(Pfizer (United States)), Mikhail Dvorkin(Budgetary Health Care Institution of the Omsk Region "Clinical Oncology Center"), Amanda Psyrri(National and Kapodistrian University of Athens), Kevin J. Harrington(Royal Marsden NHS Foundation Trust), Jean Bourhis(University of Lausanne), Robert I. Haddad(Georgetown University), Robert L. Ferris(University of Pittsburgh), Chaosu Hu(Ministry of Agriculture and Rural Affairs), JC Lin(Changhua Christian Hospital), M. Razaq(Oklahoma State University Oklahoma City), P.M-H. Chang(Taipei Veterans General Hospital), Steven De Beukelaer(Pfizer (Switzerland)), Holger Thurm(Pfizer (United States))
Cited by 42
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Defining risk levels in locally advanced head and neck cancers: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501)
|Head & Neck|2005|1.8k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k